Evidence map›Paper›PMID 25406835›Full record

ArticleChemical communications (Cambridge, England)2015

A time-resolved luminescence biosensor assay for anaplastic lymphoma kinase (ALK) activity.

Wei Cui, Laurie L Parker

Abstract read
In one paragraph

Article in Chemical communications (Cambridge, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wei CuiDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue Center for Cancer Research, Purdue University, West Lafayette, IN 47907, USA. llparker@umn.edu.
Laurie L Parker

Funding

Biosensor Assay to Screen for Signaling Pathway Inhibition in CancerR01CA182543 · NCI · UNIVERSITY OF MINNESOTA · PI PARKER, LAURIE L. · 2014 to 2018
$2.1M
Biosensor design for detection and analysis of complex signal patterns in cancerR00CA127161 · NCI · PURDUE UNIVERSITY · PI PARKER, LAURIE L. · 2010 to 2012
$785k
NCI NIH HHS R00 CA127161NCI NIH HHS R00CA127161NCI NIH HHS R01 CA182543NCI NIH HHS R01CA182543
6 · The paper itself

Abstract

A novel time-resolved luminescence biosensor assay for anaplastic lymphoma kinase (ALK) was developed. We used a straightforward strategy to modify a known ALK substrate into a peptide biosensor that can accommodate terbium luminescence sensitization upon its phosphorylation by ALK. Since this strategy is generalizable, this high-throughput screening compatible assay serves as an example for development of other kinase assays that employ terbium luminescence as a read-out.

Indexed as

Amino Acid SequenceAnaplastic Lymphoma KinaseBiosensing TechniquesEnzyme AssaysLuminescenceLuminescent MeasurementsMolecular Sequence DataPeptidesReceptor Protein-Tyrosine KinasesRecombinant ProteinsTerbiumAnaplastic Lymphoma KinasePeptidesReceptor Protein-Tyrosine KinasesRecombinant ProteinsTerbium

Identifiers

PMID25406835
PMCPMC4288484

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.